Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!


An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread - CA030-001

Updated: 5 November, 2020   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1/Phase 2


  • Gender(s)

  • 18+

    Age Range

  • 37


  • Recruiting

Treatment Options

Study Arms
Experimental: Part 1A: BMS-986249
Biological: BMS-986249
Experimental: Part 1B: BMS-986249+nivolumab (nivo)
Biological: Nivolumab Biological: BMS-986249
Experimental: Part 2A Arm A: BMS-986249+nivo then nivo
Biological: Nivolumab Biological: BMS-986249
Experimental: Part 2A Arm B: BMS-986249+nivo
Biological: BMS-986249 Biological: Nivolumab
Experimental: Part 2A Arm C: BMS-986249+nivo
Biological: Nivolumab Biological: BMS-986249
Experimental: Part 2A Arm D: ipilimumab+nivo then nivo
Biological: Ipilimumab Biological: Nivolumab
Experimental: Part 2A Arm E: Nivo
Biological: Nivolumab

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy - Eastern Cooperative Oncology Group Performance Status of 0 or 1 - Some participants must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to solid tumor histologies - Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted for some patients - Understand and sign an IRB/IEC-approved ICF prior to any study-specific evaluation - Willing and able to comply with all study procedures Exclusion Criteria: - Participants with primary CNS malignancies, tumors with CNS metastases as the only site of disease, active brain metastases, or leptomeningeal metastasis will be excluded - Active, known, or suspected autoimmune disease - Participants with other active malignancy requiring concurrent intervention. - Prior organ allograft. Other protocol defined inclusion/exclusion criteria could apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Email Us

Have questions?
Email Us